Washington Post Publisher Will Lewis Steps Down After Layoffs 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Amazon Explores AI Content Marketplace With Media Publishers 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
RANCHO CORDOVA, Calif., Feb. 26, 2018 -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the commercial launch of its AXP II system for the advanced isolation, collection and storage of hematopoietic stem cell concentrates from cord blood and peripheral blood.
“Since its introduction in 2006, our AXP system has been viewed as the gold standard in the volume reduction processing of cord blood, and we count many of the world’s leading public and private cord blood banks among our current long-time customers,” said Chris Xu, PhD, chief executive officer of Cesca Therapeutics. “Our first generation AXP system consistently achieves stem cell recovery rates in excess of 97%, the highest in the industry. With AXP II, we are introducing important enhancements to the AXP device, docking station, and proprietary XpressTRAK® software that together represent the biggest advancement in automated cord blood processing in many years. With the commercial launch of AXP II, we are continuing to fulfill our commitment to provide the highest quality, most innovative products to the cord blood bank market.”
AXP II is a complete, automated and functionally closed system that includes the AXP II device, docking station, processing set, and XpressTRAK software that maintains compliance with Current Good Manufacturing Practice (cGMP) and Current Good Tissue Practice (cGTP) regulations.
For more information, please visit: www.thermogenesis.com.
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
